TEACHERS ADVISORS, LLC - PROGENICS PHARMACEUTICALS IN ownership

PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 151 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is 1.60 and the average weighting 0.0%.

Quarter-by-quarter ownership
TEACHERS ADVISORS, LLC ownership history of PROGENICS PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2019$1,478,000
+43.2%
318,477
+29.6%
0.00%
+100.0%
Q4 2018$1,032,000
-65.9%
245,666
-49.2%
0.00%
-50.0%
Q3 2018$3,030,000
+66.8%
483,310
+113.9%
0.00%0.0%
Q2 2018$1,817,000
+11.3%
225,959
+3.3%
0.00%0.0%
Q1 2018$1,633,000
+25.6%
218,843
+0.2%
0.00%0.0%
Q4 2017$1,300,000
-14.6%
218,468
+5.6%
0.00%0.0%
Q3 2017$1,522,000
+9.1%
206,854
+0.7%
0.00%0.0%
Q2 2017$1,395,000
+22.7%
205,501
+70.6%
0.00%0.0%
Q1 2017$1,137,000
+17.6%
120,479
+7.6%
0.00%0.0%
Q4 2016$967,000
+39.9%
111,935
+2.5%
0.00%
+100.0%
Q3 2016$691,000
+49.9%
109,1660.0%0.00%0.0%
Q2 2016$461,000
+3.8%
109,166
+7.3%
0.00%0.0%
Q1 2016$444,000
-28.8%
101,7240.0%0.00%0.0%
Q4 2015$624,000
+7.2%
101,7240.0%0.00%0.0%
Q3 2015$582,000
-23.3%
101,7240.0%0.00%0.0%
Q2 2015$759,000
+24.8%
101,7240.0%0.00%0.0%
Q1 2015$608,000
-20.9%
101,7240.0%0.00%0.0%
Q4 2014$769,000
+45.6%
101,7240.0%0.00%0.0%
Q3 2014$528,000
+20.5%
101,7240.0%0.00%0.0%
Q2 2014$438,000
-2.7%
101,724
-7.5%
0.00%0.0%
Q1 2014$450,000
+8.2%
109,938
+40.8%
0.00%0.0%
Q4 2013$416,000
+10.6%
78,108
+4.4%
0.00%0.0%
Q3 2013$376,000
+31.9%
74,828
+17.0%
0.00%0.0%
Q2 2013$285,00063,9820.00%
Other shareholders
PROGENICS PHARMACEUTICALS IN shareholders Q1 2019
NameSharesValueWeighting ↓
ARMISTICE CAPITAL, LLC 6,158,000$38,611,0002.32%
ARDSLEY ADVISORY PARTNERS LP 2,045,000$12,822,0001.73%
RA Capital Management 3,030,303$19,000,0001.02%
Phocas Financial Corp. 1,736,386$10,887,0000.95%
ARDSLEY ADVISORY PARTNERS LP 500,000$3,135,0000.42%
RICE HALL JAMES & ASSOCIATES, LLC 1,345,260$8,435,0000.30%
BKS ADVISORS, LLC 115,115$721,0000.26%
PINNACLE ASSOCIATES LTD 1,530,657$9,597,0000.20%
CARILLON TOWER ADVISERS, INC. 3,948,024$24,745,0000.18%
EAGLE ASSET MANAGEMENT INC 4,444,673$27,868,0000.14%
View complete list of PROGENICS PHARMACEUTICALS IN shareholders